TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition